Conference Coverage 2025 Advancing Precision Medicine Conference, Philadelphia PA October 3-4 2025
Reporter: Stephen J. Williams, PhD
The Annual Advanced Precision Medicine Conference will be held at the Pennsylvania Convention Center October 3-4 2025 in Philadelphia PA. Advancing Precision Medicine is an organization dedicated to provide education and discourse among medical professionals to advance the field of precision therapeutics and diagnostics in cancer, cardiovascular, and other diseases. The Annual symposium is held in Philadelphia.
The event will consist of two parallel tracks composed of keynote addresses, panel discussions and fireside chats which will encourage audience participation. Over the course of the two-day event leaders from industry, healthcare, regulatory bodies, academia and other pertinent stakeholders will share an intriguing and broad scope of content.
This event will consist of three immersive tracks, each crafted to explore the multifaceted dimensions of precision medicine. Delve into Precision Oncology, where groundbreaking advancements are reshaping the landscape of cancer diagnosis and treatment. Traverse the boundaries of Precision Medicine Outside of Oncology, as we probe into the intricate interplay of genetics, lifestyle, and environment across a spectrum of diseases and conditions including rare disease, cardiology, ophthalmology, and neurodegenerative disease. Immerse yourself in AI for Precision Medicine, where cutting-edge technologies are revolutionizing diagnostics, therapeutics, and patient care. Additionally, explore the emerging frontiers of Spatial Biology and Mult-Omics, where integrated approaches are unraveling the complexities of biological systems with unprecedented depth and precision.
https://www.advancingprecisionmedicine.com/
Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at
using the following meeting hashtags
#AdvancingPM #precisionmedicine #WINSYMPO2025
APM is a mission-driven team dedicated to advancing clinical practice through education in precision medicine, oncology, and pathology. Our expert-led programs bring together clinicians, pathologists, pharmacists, nurses, and researchers from across the country.
What We Offer
In 2025, we’re proud to offer three specialized event series—each tailored to a different corner of the healthcare ecosystem:
Register here for the 2025 Conference: https://www.advancingprecisionmedicine.com/apm-home/apm-annual-conference-and-exhibition-in-philadelphia/
Where discovery meets application – and science transforms lives.
What’s New in 2025?
Four Specialized Tracks:
Track 1 – 2025 WIN Symposium: Progress and Challenges in Precision Oncology
Presented in partnership with Advancing Precision Medicine
As the official 2025 WIN Symposium, this dedicated track will explore the evolving landscape of precision oncology, highlighting both groundbreaking advances and the ongoing challenges of translating molecular insights into clinical impact. Curated by the WIN Consortium, the program will feature global leaders in cancer research, diagnostics, and therapeutic innovation—offering a comprehensive view of how precision medicine is reshaping oncology across tumor types and care settings.
Track 2 – Day 1 – Multi-Omics Integration, Day 2 – Precision Medicine Outside of Oncology
From genomics and transcriptomics to proteomics and metabolomics—this track highlights how multi-layered data is revolutionizing systems biology and clinical decision-making.
Diving into applications across cardiovascular, neurology, rare disease, infectious disease, and other therapeutic areas where precision tools are reshaping clinical practice.
Why Attend?
- Cutting-Edge Innovation: Explore AI-powered solutions, multi-omics workflows, clinical trial design, and real-world implementation.
- Renowned Speakers: Hear from global thought leaders in translational research, biotech innovation, and personalized therapeutics.
- Dynamic Format: Keynotes, fireside chats, panels, and audience-interactive discussions across four concurrent tracks.
- Unmatched Networking: Collaborate with scientists, startups, executives, regulators, and investors shaping tomorrow’s care.
- Philadelphia Advantage: Centrally located near premier academic institutions, hospitals, incubators, and venture capital networks.
Who Should Attend?
Researchers, clinicians, data scientists, regulatory experts, startup founders, investors, tech transfer professionals, and healthcare leaders.
Let’s advance a future that is more predictive, preventive, and precise—together.
2019 Nobel Laureate
Sidney Farber Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute
Senior Physician-Scientist at Brigham and Women’s Hospital
Howard Hughes Medical Institute Investigator
William Kaelin is the Sidney Farber Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, Senior Physician-Scientist at Brigham and Women’s Hospital and Howard Hughes Medical Institute Investigator. He obtained his undergraduate and M.D. degrees from Duke University and completed his training in Internal Medicine at the Johns Hopkins Hospital, where he served as chief medical resident. He was a clinical fellow in Medical Oncology at the Dana-Farber Cancer Institute and later a postdoctoral fellow in David Livingston’s laboratory, during which time he was a McDonnell Scholar.
A Nobel Laureate, Dr. Kaelin received the 2019 Nobel Prize in Physiology or Medicine. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the National Academy of Medicine, the American Society of Clinical Investigation, and the American College of Physicians. He previously served on the National Cancer Institute Board of Scientific Advisors, the AACR Board of Trustees, and the Institute of Medicine National Cancer Policy Board. He is a recipient of the Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center; the Richard and Hinda Rosenthal Prize from the AACR; the Doris Duke Distinguished Clinical Scientist award; the 2010 Canada International Gairdner Award; ASCI’s Stanley J. Korsmeyer Award; the Scientific Grand Prix of the Foundation Lefoulon-Delalande; the Wiley Prize in Biomedical Sciences; the Steven C. Beering Award; the AACR Princess Takamatsu Award; the ASCO Science of Oncology Award; the Helis Award; the Albert Lasker Basic Medical Research Prize; the Massry Prize; the Harriet P. Dustan Award for Science as Related to Medicine from the American College of Physicians.
Dr. Kaelin’s research seeks to understand how, mechanistically, mutations affecting tumor-suppressor genes cause cancer. His laboratory is currently focused on studies of the VHL, RB-1, and p53 tumor suppressor genes. His long-term goal is to lay the foundation for new anticancer therapies based on the biochemical functions of such proteins. His work on the VHL protein helped to motivate the eventual successful clinical testing of VEGF inhibitors for the treatment of kidney cancer. Moreover, this line of investigation led to new insights into how cells sense and respond to changes in oxygen, and thus has implications for diseases beyond cancer, such as anemia, myocardial infarction, and stroke. His group also showed that leukemic transformation by mutant IDH was reversible, setting the stage for the development and approval of mutant IDH inhibitors, and discovered how thalidomide-like drugs kill myeloma cells by degrading two otherwise undruggable transcription factors,
2025 Steering Committee
Presentations
A diverse group of more than 90 key opinion leaders will convene to explore the critical forces shaping the future of healthcare. Representing a range of disciplines—including genomics, bioinformatics, clinical research, biopharma, technology, and investment—these experts will lead discussions on the latest advancements and challenges in precision medicine.
Topics will include the evolution of genomic sequencing technologies, ethical considerations in managing patient data, the integration of AI in diagnostics, and strategies for translating innovation into clinical practice. The inclusion of investors and strategic partners will also bring a vital perspective on funding models, commercialization pathways, and the acceleration of cutting-edge therapies. Together, these voices will offer a comprehensive view of the trends transforming personalized healthcare on a global scale.
Networking Opportunities
Our precision medicine event, hosting over 500 attendees, offers invaluable networking opportunities. Bringing together professionals, researchers, and industry leaders, the event facilitates engaging discussions, knowledge-sharing, and potential partnerships, driving advancements in precision medicine.
Why Exhibit
Exhibiting at the event provides a unique opportunity to showcase your cutting-edge solutions and connect with key stakeholders in the rapidly advancing field of personalized healthcare. As an exhibitor, you’ll gain visibility among industry leaders, researchers, and professionals, allowing you to forge strategic partnerships, highlight your contributions to precision medicine, and stay at the forefront of innovations shaping the future of healthcare. Don’t miss the chance to position your company as a leader in this dynamic and transformative space, driving meaningful collaborations and contributing to the advancement of precision medicine.
THE LOCATION
APM Annual Conference 2025
Pennsylvania Convention Center
1101 Arch Street
Philadelphia, PA 19107
Registration Fees
Student – free
Academic/Government/Non-Profit – free
Healthcare Providers – free
Investors – free
Vendor/Technology Provider $999
Other Live Conference Proceedings can be found on this Online Open Access Journal at:
including a list of previous conference at:
Part Two: List of BioTech Conferences 2013 to Present
including Live Coverage of the 2024 Advancing Precision Medicine conference at:
Real Time Coverage Advancing Precision Medicine Annual Conference, Philadelphia PA November 1,2 2024
2012pharmaceutical
sjwilliamspa